Skinbac
Probiotical - Linkedin Probiotical - E-mail

PROBIAL BABY Colic Forte

← Back to research page

Pediatrics

Developed Formulas
Benefits
  • Targeted inhibition of coliform bacteria isolated from colicky infants
  • Supports mucosal functionality
  • Anti-inflammatory properties
Pediatrics
Ready to market
Pediatrics
Clinical test
Pediatrics
Microbac
Pediatrics
In vitro test
Pediatrics
Allergen Free
Pediatrics
Real time stability
Pediatrics
Strain in oil
Components

Bifidobacterium breve BR03 (DSM 16604)
Lacticaseibacillus rhamnosus GG (ATCC53103)
Limosilactobacillus reuteri LRE02 (DSM 23878)

Label Claim

Food supplement with probiotic strains.

Effective nutraceutical combination
Scientific Rationale
In vitro studies

PROBIAL® BABY Colic Forte is a specialized blend of three probiotic strains, each with evidence supporting their role in alleviating gaseous colic in newborns:

  • Bifidobacterium breve BR03: Colicky infants often have higher levels of gas-producing coliforms compared to healthy babies. B. breve counters these pathogens through the secretion of organic acids and antimicrobial substances [1,2]. In in vitro studies, BR03 has demonstrated the ability to inhibit pathogenic E. coli [3-5]. Furthermore, in an in vivo study alongside another B. breve strain, it significantly counteracted the growth of Enterobacteriaceae isolated from colicky infants and reduced total fecal coliforms [6].

  • Lacticaseibacillus rhamnosus GG: This is one of the most extensively researched probiotic strains, particularly in relation to pediatric diarrhea. It boasts over 1000 publications and 300 clinical studies [7].

Limosilactobacillus reuteri LRE02: Known for its antipathogenic activity, this specific strain of L. reuteri also has the unique ability to produce vitamin B12, which is beneficial for mucosal health [8,9].

Bibliography

1. Nicola S. et al. Interaction between probiotics and human immune cells: the prospective anti-inflammatory activity of Bifidobacterium breve BR03. AgroFOOD, 2010; 21(2):S44-47

2. Bozzi Cionci N, et al. Therapeutic Microbiology: The Role of Bifidobacterium breve as Food Supplement for the Prevention/Treatment of Paediatric Diseases. Nutrients. 2018 Nov 10;10(11):1723. doi: 10.3390/nu10111723

3. Amoruso A. et al. A Systematic Evaluation of the Immunomodulatory and Functional Properties of Probiotic Bifidobacterium Breve BR03 (DSM 16604) Lactobacillus plantarum LP01 (LMG P-21021). J Prob Health. 2019;  7:214. Doi: 10.35248/2329-8901.19.7.214

4. Del Piano M., et al. In vitro sensitivity of probiotics to human pancreatic juice. J Clin Gastroenterol. 2008;42 Suppl 3 Pt 2:S170-S173. doi:10.1097/MCG.0b013e3181815976.

5. Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains (LP01, LP02, LR04, LR06, LPS01, LDD01, BR03, B632). J Clin Gastroenterol. 2012; 46 Suppl:S29-32

6. Mogna L. et al. Capability of the two microorganisms Bifidobacterium breve B632 and Bifidobacterium breve BR03 to colonize the intestinal microbiota of children. J Clin Gastroenterol. 2014;48 Suppl 1:S37-S39. doi:10.1097/MCG.0000000000000234 

7. Capurso L. Thirty Years of Lactobacillus rhamnosus GG: A Review. J Clin Gastroenterol. 2019 Mar;53 Suppl 1:S1-S41. Doi: 10.1097/MCG.0000000000001170

8. Deidda F, et al. How Probiotics may Kill Harmful Bacteria: The in vitro Activity against Some Haemolytic Strains. J Prob Health, 2020. Vol. 8 Iss.2 No: 216.  DOI: 10.35248/2329-8901.20.8.216

9. Internal Probiotical data

Associations